Inés González González-Suárez

Dr. Inés González González-Suárez

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2016 in The Lancet Neurology
Verified
Journal Article
Closed access
EMElena H Martinez-Lapiscina
Elena H Martinez-Lapiscina
SASam Arnow
Sam Arnow
JWJames A Wilson
James A Wilson
SSShiv Saidha
Shiv Saidha
JPJana Lizrova Preiningerova
Jana Lizrova Preiningerova
PVPablo Villoslada
Pablo Villoslada

12 June 2016 in Cephalalgia
Verified
Journal Article
Closed access
MCMaría Luz Cuadrado
María Luz Cuadrado
AAAngel Aledo-Serrano
Angel Aledo-Serrano
PNPatricia Navarro
Patricia Navarro
PLPedro López-Ruiz
Pedro López-Ruiz
César Fernandez-de-las-PeñasCésar Fernandez-de-las-Peñas
César Fernandez-de-las-Peñas
CPCristina Fernandez Perez
Cristina Fernandez Perez
Greater occipital nerve (GON) blocks are widely used for the treatment of headaches, but quality evidence regarding their efficacy is scarce. The objective of this article is to assess the short-term clinical efficacy of GON anaesthetic blocks in chronic migraine (CM) and to analyse their effect on pressure pain thresholds (PPTs) in different territories. The study was designed as a double-blind, randomised, placebo-controlled clinical trial. Thirty-six women with CM were treated either with bilateral GON block with bupivacaine 0.5% (n = 18) or a sham procedure with normal saline (n = 18). Headache frequency was recorded a week after and before the procedure. PPT was measured in cephalic points (supraorbital, infraorbital and mental nerves) and extracephalic points (hand, leg) just before the injection (T0), one hour later (T1) and one week later (T2). Anaesthetic block was superior to placebo in reducing the number of days per week with moderate-or-severe headache (MANOVA; p = 0.027), or any headache (p = 0.04). Overall, PPTs increased after anaesthetic block and decreased after placebo; after the intervention, PPT differences between baseline and T1/T2 among groups were statistically significant for the supraorbital (T0–T1, p = 0.022; T0–T2, p = 0.031) and infraorbital sites (T0–T1, p = 0.013; T0–T2, p = 0.005). GON anaesthetic blocks appear to be effective in the short term in CM, as measured by a reduction in the number of days with moderate-to-severe headache or any headache during the week following injection. GON block is followed by an increase in PPTs in the trigeminal area, suggesting an effect on central sensitisation at the trigeminal nucleus caudalis. This trial is registered at ClinicalTrials.gov (NCT02188394).

22 July 2013 in BMC Neurology
Verified
Journal Article
Open access
PDF file
IGInés González González-Suárez
Inés González González-Suárez
ISIrene Sanz-Gallego
Irene Sanz-Gallego
FRFrancisco Javier Rodríguez de Rivera
Francisco Javier Rodríguez de Rivera
JAJavier Arpa
Javier Arpa
Guillain-Barre syndrome (GBS) is characterized by acute onset and progressive course, and is usually associated with a good prognosis. However, there are forms of poor prognosis, needing ventilatory support and major deficits at discharge. With this study we try to identify the factors associated with a worse outcome. 106 cases of GBS admitted in our hospital between years 2000–2010 were reviewed. Epidemiological, clinical, therapeutical and evolutionary data were collected. At admission 45% had severe deficits, percentage which improves throughout the evolution of the illness, with full recovery or minor deficits in the 87% of patients at the first year review. Ages greater than 55 years, severity at admission (p < 0.001), injured cranial nerves (p = 0.008) and the needing of ventilator support (p = 0.003) were associated with greater sequels at the discharge and at the posterior reviews in the following months. 17% required mechanical ventilation (MV). Values < 250 L/min in the Peak Flow-test are associated with an increased likelihood of requiring MV (p < 0.001). Older age, severe deficits at onset, injured cranial nerves, requiring MV, and axonal lesion patterns in the NCS were demonstrated as poor prognostic factors. Peak Flow-test is a useful predictive factor of respiratory failure by its easy management.

4 March 2021 in Neurology Neuroimmunology & Neuroinflammation
Verified
Journal Article
Open access
PDF file
JFJosé I. Fernández-Velasco
José I. Fernández-Velasco
JKJens Kuhle
Jens Kuhle
EMEnric Monreal
Enric Monreal
VMVirginia Meca-Lallana
Virginia Meca-Lallana
JMJOSE EUSTASIO MECA-LALLANA
JOSE EUSTASIO MECA-LALLANA
LVLuisa M. Villar
Luisa M. Villar
Objective To analyze the changes induced by ocrelizumab in blood immune cells of patients with primary progressive MS (PPMS). Methods In this multicenter prospective study including 53 patients with PPMS who initiated ocrelizumab treatment, we determined effector, memory, and regulatory cells by flow cytometry at baseline and after 6 months of therapy. Wilcoxon matched paired tests were used to assess differences between baseline and 6 months9 results. p Values were corrected using the Bonferroni test. Results Ocrelizumab reduced the numbers of naive and memory B cells (p < 0.0001) and those of B cells producing interleukin (IL)-6, IL-10, granulocyte-macrophage colony-stimulating factor (GM-CSF), and tumor necrosis factor-alpha (TNFα) (p < 0.0001 in all cases). By contrast, the proportions of plasmablasts and B cells producing GM-CSF and TNFα increased significantly, suggesting the need for treatment continuation. We also observed a decrease in CD20+ T-cell numbers (p < 0.0001) and percentages (p < 0.0001), and a clear remodeling of the T-cell compartment characterized by relative increases of the naive/effector ratios in CD4+ (p = 0.002) and CD8+ (p = 0.002) T cells and relative decreases of CD4+ (p = 0.03) and CD8+ (p = 0.004) T cells producing interferon-gamma. Total monocyte numbers increased (p = 0.002), but no changes were observed in those producing inflammatory cytokines. The immunologic variations were associated with a reduction of serum neurofilament light chain (sNfL) levels (p = 0.008). The reduction was observed in patients with Gd-enhanced lesions at baseline and in Gd− patients with baseline sNfL >10 pg/mL. Conclusions In PPMS, effector B-cell depletion changed T-cell response toward a low inflammatory profile, resulting in decreased sNfL levels.

14 March 2017 in Brain and Behavior
Verified
Journal Article
Open access
PDF file
IGInés González González-Suárez
Inés González González-Suárez
LALuis Rodríguez De Antonio
Luis Rodríguez De Antonio
AOAida Orviz
Aida Orviz
SMSara Moreno-García
Sara Moreno-García
MVMaría D Valle-Arcos
María D Valle-Arcos
COCelia Oreja-Guevara
Celia Oreja-Guevara
Introduction: Natalizumab (NTZ) is an effective drug for the treatment of relapsing‐remitting multiple sclerosis. In some patients discontinuation is mandatory due to the risk of progressive multifocal leukoencephalopathy. However, severe clinical and radiological worsening has been described after drug cessation. Our aim was to describe the clinical and radiological features of the rebound phenomenon.Material and Methods: Patients switched fromNTZto Fingolimod (FTY) who had presented a rebound after discontinuation were selected. Clinical and magnetic resonance imaging (MRI) data were collected.Results: FourJCvirus positive patients were included. The mean disease duration was 9.5 years (SD: 4.12) with a mean time of 3.1 years onNTZ. All patients startedFTYwithin 3–4 months. Neurological deterioration started in a mean time of 3.5 months (SD: 2.08) with multifocal involvement: 75% motor disturbances, 50% cognitive impairment, 25% seizures. The average worsening in Expanded Disability Status Scale [EDSS] was of 3.25 points (SD: 2.33). TheMRIshowed a very large increase in T2 and gadolinium‐enhanced lesions (mean: 23.67,SD: 18.58). All patients received 5 days of IV methylprednisolone, one patient required plasma exchange. All the patients presented neurological deterioration with anEDSSworsening of 1.13 points (SD: 0.48). After the rebound three patients continued treatment withFTY, only one patient restartedNTZ.Conclusion: Discontinuation ofNTZtreatment may trigger a severe rebound with marked clinical and radiological worsening. A very careful evaluation of benefit‐risk should be considered beforeNTZwithdrawal, and a close monitoring and a short washout period is recommended after drug withdrawal.

26 September 2013 in The Cerebellum
Verified
Journal Article
Closed access
PDF file
IGInés González González-Suárez
Inés González González-Suárez
MAM. J. Aguilar-Amat
M. J. Aguilar-Amat
MTM. Trigueros
M. Trigueros
Alberto M BorobiaAlberto M Borobia
Alberto M Borobia
ACA. Cruz
A. Cruz
JAJ. Arpa
J. Arpa